CXCR7 antagonism ameliorates the clinical severity of EAE. Dose response effects of the CXCR7 antagonist, CCX771, were evaluated during induction of and after treatment of ongoing adoptive transfer EAE. (A) Animals were grouped into those receiving daily treatment with saline (yellow), vehicle (red) or CCX771 at 5 mg/kg (green) or 10 mg/kg (blue) beginning at the time of adoptive transfer or when animals reached a score of 1 (purple). Results are expressed as mean clinical score ± SEM, n = 5. Two-way ANOVA for all treatment groups showed a strong interaction of treatment and days post-adoptive transfer with disease progression: interaction: F = 2.201, P < 0.0001; antagonist treatment: F = 93.85, P < 0.0001; days post-adoptive transfer: F = 59.06, P < 0.0001. (B) Comparison between the mean highest severity scores of effector phase (red bracket on A) and recovery phase (blue bracket on A). Results are expressed as mean highest severity score ± SEM. Two-way ANOVA P values summary: interaction: F = 1.71, P = 0.1659; disease phase: F = 164.57, P < 0.0001; treatment: F = 22.21, P < 0.0001).